{"preliminary_commentary":{"by_channel":{"youtube":8,"x_thread":8,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05572229\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IFM2021-01","nct_id":"NCT05572229","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ifm2021-01-nct05572229. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IFM2021-01","arms":[{"description":"For patients assigned to cohort A (Tec-Dara) patients will receive Tec-Dara until documented PD or unacceptable toxicity","label":"Tec-Dara","type":"EXPERIMENTAL"},{"description":"For patients assigned to cohort B (Tec-Len) patients will receive Tec-Len until documented PD or unacceptable toxicity","label":"Tec-Len","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica N.V., Belgium"],"completion_date":{"date":"2032-09","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":74,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Teclistamab","otherNames":["JNJ-64007957"],"type":"DRUG"},{"name":"Daratumumab","otherNames":[],"type":"DRUG"},{"name":"Lenalidomide","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"University Hospital, Lille","official_title":"A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len","timeFrame":"At the end of 4 th cycle (each cycle is 28 days), an average 4 months"}],"references":[],"start_date":{"date":"2023-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05572229"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ifm2021-01-nct05572229"}